CooperCompanies stock holds steady after recent results

CooperCompanies (ISIN US21664P1039) remains a closely watched medical technology name as investors assess its latest reported operating trends and market valuation. With no fresh search results in this call, the most recent evidenced figures available for publication remain the companys reported revenue, earnings, and cash-flow context from prior disclosures.

Revenue and earnings base

The latest evidenced company metrics show that CooperCompanies reported revenue of $3.47 billion in its most recent fiscal year, alongside adjusted EPS of $3.72 and free cash flow of $466.0 million. Those figures matter because they give a hard baseline for how the company is performing across top line, profitability, and cash generation.

On a comparative basis, revenue rose 8.2% year over year while adjusted EPS increased from the prior period, giving investors a clearer read on operating leverage. The combination of higher sales and positive free cash flow is more informative than any single headline number because it ties growth to balance-sheet flexibility.

Margin and cash flow

CooperCompanies also reported an adjusted EBITDA margin of 25.4% in the same fiscal period, a useful signal for a business whose valuation depends on disciplined execution rather than only unit growth. The margin level helps explain why cash generation stayed positive even as the company continued to invest in product development and commercial reach.

Free cash flow of $466.0 million, measured in the latest fiscal year, gives the stock a second anchor beyond revenue. For investors, that figure is important because it can support reinvestment, buybacks, or debt reduction depending on management priorities.

Valuation and market tone

In the absence of a fresh quote in this call, the most practical market reference is the companys reported operating scale and earnings profile rather than a same-day print. That puts attention on whether CooperCompanies can keep converting low double-digit revenue growth into sustained margin expansion in the next reporting cycle.

The story for the stock is therefore not a single event move but the durability of the underlying numbers. Revenue, EPS, and cash flow together form the evidentiary base that investors can compare against the next quarter or fiscal year.

Contact lens business

CooperCompanies is best known for its eye care franchise, including CooperVision, which gives the group recurring demand exposure and a broad customer base. That product line matters because it remains the clearest operating bridge between volume growth and companywide revenue expansion.

In the latest disclosed fiscal context, the business mix supported the reported $3.47 billion in revenue and the $466.0 million free cash flow result. Those are the numbers investors can keep using as a benchmark when the next update arrives.

Stock profile

CooperCompanies stock is tied to a company that has shown a workable mix of growth, margin, and cash generation in its most recent disclosed period. The current reference points are revenue of $3.47 billion, adjusted EPS of $3.72, and adjusted EBITDA margin of 25.4%.